Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer

Publication Date: August 8, 2016

Key Points

Key Points

Nearly 75% of women with ovarian cancer are diagnosed with advanced stage disease (International Federation of Gynecology and Obstetrics [FIGO] IIIC or IV) at presentation.

Recently two randomized clinical trials (RCTs) demonstrated that neoadjuvant chemotherapy (NACT) was noninferior to primary cytoreductive surgery (PCS) with respect to progression-free and overall survival and resulted in a lower incidence of treatment-related morbidity and mortality.

However, both trials have been criticized because the median overall survival, mean operative time, and rates of optimal cytoreduction were lower than expected.

This Guideline provides guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.

Assessment

...essment...

...with suspected stage IIIC or IV in...


...nical evaluation should include a comp...


Treatment

...eatment

...ble 1. Risk Factors for Perioperative Mo...


...who have a high perioperative risk...


...hat women are not eligible for med...


...who are fit for PCS, with potentially rese...


...with a high likelihood of achieving cytoreduction...


...n who are fit for PCS but are deemed...


...s delivered, all patients should have histo...


...a platinum/taxane doublet is recommended. (...


...rgery following three or four cycles of ch...


...ients with progressive disease on...


...ical Evaluation and Treatment of Women...